Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Elizabeth A. Harden"'
Autor:
Lauren L. Siewertsz van Reesema, Vasilena Zheleva, Janet S. Winston, Rick J. Jansen, Carolyn F. O’Connor, Andrew J. Isbell, Minglei Bian, Rui Qin, Patricia T. Bassett, Virginia J. Hinson, Kimberly A. Dorsch, Brad W. Kirby, Robert E. Van Sciver, Angela M. Tang-Tan, Elizabeth A. Harden, David Z. Chang, Cynthia A. Allen, Roger R. Perry, Richard A. Hoefer, Amy H. Tang
Publikováno v:
EBioMedicine, Vol 11, Iss C, Pp 183-198 (2016)
Background: Metastatic breast cancer exhibits diverse and rapidly evolving intra- and inter-tumor heterogeneity. Patients with similar clinical presentations often display distinct tumor responses to standard of care (SOC) therapies. Genome landscape
Externí odkaz:
https://doaj.org/article/65a73692ab8c408685ec6d1a14fec41e
Autor:
Michele Tracy Berger, Elizabeth A. Harden, Keval Kaur Khalsa, Kibby McMahon, Sat Bir S. Khalsa
Publikováno v:
Journal of Child and Family Studies. 30:711-722
Adolescence is a critical age for developing difficulties with emotion regulation and other psychosocial problems. Yoga programs implemented in schools may be a promising method of intervention, as previous research suggests that they improve emotion
Publikováno v:
International Journal of Surgery Case Reports
Introduction A BRCA-2 mutation carrier with a metachronous pancreatic adenocarcinoma (PC) and established peritoneal metastases is presented. Combined modality therapy including Cytoreductive Surgery (CS) and Hyperthermic Intraperitoneal Chemotherapy
Autor:
Brad W. Kirby, Andrew J. Isbell, David Z. Chang, Virginia J. Hinson, Richard A. Hoefer, Robert E. Van Sciver, Carolyn F. O’Connor, Rick J. Jansen, Minglei Bian, Cynthia A. Allen, Vasilena Zheleva, Rui Qin, Patricia T. Bassett, Janet S. Winston, Angela M. Tang-Tan, Roger R. Perry, Amy H. Tang, Lauren L. Siewertsz van Reesema, Elizabeth A. Harden, Kimberly A. Dorsch
Publikováno v:
EBioMedicine, Vol 11, Iss C, Pp 183-198 (2016)
EBioMedicine
EBioMedicine
Background Metastatic breast cancer exhibits diverse and rapidly evolving intra- and inter-tumor heterogeneity. Patients with similar clinical presentations often display distinct tumor responses to standard of care (SOC) therapies. Genome landscape
Publikováno v:
AAOHN Journal. 38:409-418
The workplace offers a unique setting in which to offer CVD risk reduction programs. Marketing these programs involves at least two distinct processes. First, a corporation must agree to accept and support workplace health programming. Second, workpl
Publikováno v:
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.). 203(3)
The kidneys of streptozotocin (STZ)-diabetic rats are resistant to certain toxic effects of the antineoplastic drug cisplatin. The mechanism is unknown. This study used the galactosemic rat model to test the hypothesis that the apparent diabetes-indu
Autor:
Randall F. Dryer, Victor L. Zirilli, Alan E. Schlesinger, Kim D. Murphy, Beverly M. Genez, Elizabeth A. Harden
Publikováno v:
Skeletal Radiology. 17:306-309
Autor:
Barton F. Haynes, Jacqueline Whang-Peng, Elizabeth A. Harden, Joanne Kurtzberg, Joseph O. Moore, Michael S. Hershfield
Publikováno v:
Proceedings of the National Academy of Sciences. 81:253-257
Selective failure of lymphoid development occurs in genetic deficiency of adenosine deaminase (ADA). We examined the in vivo effects of a potent inhibitor of ADA, 2'-deoxycoformycin, which was used to treat a patient with refractory acute leukemia. U
Autor:
Gerald L. Messerschmidt, Elizabeth A. Harden, Mary B. Daly, James M. Thompson, Richard S. Leff, David B. Johnson, Richard J. Mercier
Publikováno v:
Cancer. 62:32-35
Etoposide (VP-16-213) has been used in the treatment of many solid tumors and hematologic malignancies. When used in high doses and in conjunction with autologous bone marrow transplantation, this agent has activity against several treatment-resistan
Autor:
Kazuyuki Naito, Andrew J. Laster, Elizabeth A. Harden, Bo DuPont, Thomas J. Palker, Winifred Ho, Barton F. Haynes
Publikováno v:
Blood. 66:642-648
Antibody 3–40 defines a 35- to 40-kd surface antigen present on T lymphoblastic leukemia (T-ALL) cells that is absent on normal hematopoietic cells (Naito et al, Blood 62:852, 1983). Using immunoblot analysis of cytoskeletal proteins and indirect i